Low-dose (7.5 mg) oral methotrexate for chronic progressive multiple sclerosis. Design of a randomized, placebo-controlled trial with sample size benefits from a composite outcome variable including preliminary data on toxicity.
about
Glatiramer acetate in treatment of multiple sclerosis: a toolbox of random co-polymers for targeting inflammatory mechanisms of both the innate and adaptive immune system?Development of a Sensitive Outcome for Economical Drug Screening for Progressive Multiple Sclerosis Treatment.Role of steroids and immunosuppression and effects of interferon beta-1b in multiple sclerosis.
P2860
Low-dose (7.5 mg) oral methotrexate for chronic progressive multiple sclerosis. Design of a randomized, placebo-controlled trial with sample size benefits from a composite outcome variable including preliminary data on toxicity.
description
1992 nî lūn-bûn
@nan
1992 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
1992 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
1992年の論文
@ja
1992年論文
@yue
1992年論文
@zh-hant
1992年論文
@zh-hk
1992年論文
@zh-mo
1992年論文
@zh-tw
1992年论文
@wuu
name
Low-dose (7.5 mg) oral methotr ...... preliminary data on toxicity.
@ast
Low-dose (7.5 mg) oral methotr ...... preliminary data on toxicity.
@en
type
label
Low-dose (7.5 mg) oral methotr ...... preliminary data on toxicity.
@ast
Low-dose (7.5 mg) oral methotr ...... preliminary data on toxicity.
@en
prefLabel
Low-dose (7.5 mg) oral methotr ...... preliminary data on toxicity.
@ast
Low-dose (7.5 mg) oral methotr ...... preliminary data on toxicity.
@en
P2093
P1476
Low-dose (7.5 mg) oral methotr ...... preliminary data on toxicity.
@en
P2093
Daughtry MM
Goodkin DE
Schwetz KM
Van Dyke C
VanderBrug Medendorp S
P304
[7723 words; 89 paragraphs]
P478
P577
1992-09-01T00:00:00Z